NeurologyLive® Friday 5 — May 8, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Friedreich Ataxia, Early Diagnosis, and Communicating Complex Neurologic Diseases: Bill Nye

Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]

2: New National Program Targets Nutrition Access in Myasthenia Gravis Community

In a recent Q&A, Aprill Lane, US Advocacy Lead for Rare Disease at UCB, discusses a new national initiative aimed at improving nutrition access and reducing daily disease burden for patients with myasthenia gravis.

3: Ongoing Pediatric Epilepsy Research Consortium Initiatives and the Future of Pediatric Epilepsy Care: Anup Patel, MD

In a recent interview at AAN 2026, Anup Patel, MD, associate chief quality officer at Nationwide Children’s Hospital, discussed how AI-driven research initiatives within PERC are helping identify missed epilepsy diagnoses and improve care pathways in pediatric populations. [WATCH TIME: 3 minutes]

4: Phase 3 METEROID Insights: Satralizumab Positions Itself as Potential First Approved Therapy for MOGAD

In a recent Q&A, neurologist Michael Levy, MD, PhD, associate professor at Harvard Medical School and Massachusetts General Hospital, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

5: Beyond Neurodegeneration: GLP-1 Receptor Agonists Find Their Footing in Stroke, Sleep, and Intracranial Pressure Disorders

In a new guest feature, Rani Priyanka Vasireddy, MD, MHA, and Shilpa Chitnis, MD, PhD, discuss the growing relevance of GLP-1 receptor agonists in neurology, with the strongest evidence in stroke prevention and obstructive sleep apnea, and emerging signals in idiopathic intracranial hypertension and migraine.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!